Doctors and patients are facing challenges due to the lack of FDA-approved testosterone products for women in the U.S., leading many women to seek testosterone therapy for menopause symptoms like low sexual desire. At a recent FDA workshop, concerns were raised about insurance denials, off-label prescribing, and dosing difficulties when using male formulations. Dr. Kudzai Dombo, an obstetrician-gynecologist from Los Angeles, describes how patients often ask about testosterone after starting estrogen and progesterone treatments, but she faces hurdles like administrative burdens and high costs due to the lack of standardized female-specific options.
Written locally by qwen2.5:14b on 2026-09-19,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
FDA convened a public workshop to examine the rising off-label use of testosterone among menopausal women, amid concerns over its long-term safety. Clinicians are prescribing testosterone products designed for men at smaller doses due to a lack of FDA-approved formulations for women in the U.S. Studies show that while adult males have about 15 times more total testosterone than females, this hormone is still abundant in premenopausal women, produced at roughly three times the rate of estrogen. As women age and their testosterone levels decline, they may experience bone density loss, muscle mass reduction, cognitive decline, mood changes, sexual dysfunction, and decreased energy. Dr. Christina Chang from FDA's Center for Drug Evaluation and Research warned that there are no approved uses for testosterone therapy specifically for menopausal women in the U.S., highlighting the need for more research on its safety and efficacy.
Written for “Testosterone Use For Menopause Symptoms” on 2026-10-04,
grounded in this article and the 1 other(s) covering the same event.
When women ask their doctors about taking testosterone to help with menopause symptoms, they can run into insurance rejections, confusing workarounds and dosing guesswork, as no testosterone product is FDA-approved for women in the U.S.
On Thursday, the Food and Drug Administration (FDA) convened a public workshop to examine the evidence, safety and research gaps surrounding testosterone therapy for menopausal women.
asserted
Administration → ask → women
Interest in testosterone therapy has grown as more women seek treatment for symptoms such as low sexual desire, fatigue and reduced quality of life during menopause — yet the lack of an FDA-approved product has left physicians relying on off-label prescribing and compounded formulations.
asserted
lack → grow → prescribing
Dr. Kudzai Dombo, a board-certified obstetrician-gynecologist, Menopause Society-certified practitioner, and prescribing physician at Alloy Health, said she sees this dynamic playing out daily in her own Los Angeles practice.
asserted
dynamic → certify → practice
Once patients get settled on standard estrogen and progesterone regimens, "The immediate next question is, do I need testosterone?" Dombo told Fox News Digital.
asserted
Dombo → settle → Digital
Although women may hear about a wide range of potential benefits on social media and from friends, current evidence-based guidelines support testosterone therapy for only one indication: hypoactive sexual desire disorder (HSDD), or persistently low sexual desire.
uncertain
guidelines → hear → indication
Clinical evidence supporting its use for energy, mood, bone health or sleep remains limited — though many patients are eager to try it for those secondary benefits, according to Dombo.
uncertain
patients → support → Dombo
Because no female-specific formulation exists, doctors must navigate off-label workarounds.
asserted
doctors → exist → workarounds
They typically choose between using custom compounding pharmacies or micro-dosing FDA-approved male gel packets, which patients must carefully measure out at home.
asserted
patients → choose → home
This lack of standardized options creates administrative and financial hurdles.
asserted
lack → create → hurdles
Because the therapy is off-label, insurance routinely denies coverage, forcing clinicians and patients to improvise — a frustration that Dombo experienced firsthand.
asserted
Dombo → deny → that
"When I was prescribed testosterone, my insurance denied coverage, and my physician recommended a compounded cream to avoid the administrative burden," Dombo recalled.
asserted
Dombo → prescribe → burden
"I said, 'Well, I've already tried compounded and I actually want to try the gel.'
asserted
I → say → gel
Using a discount coupon, she paid out of pocket and discovered that a 10-month supply of male gel packets was actually cheaper than a single month of compounded cream.
asserted
supply → use → cream
"It's just an example, I think, of how we have to adapt to a system that has not supported patients when it comes to access to testosterone therapy," she said.
asserted
she → think → therapy
Dosing male products can also present clinical challenges.
asserted
Dosing → dose → challenges
Dombo described a patient in her private practice who precisely measured out one-tenth of a male gel packet daily using a syringe.
asserted
who → describe → syringe
Despite three months of consistency, follow-up bloodwork showed no change in hormone levels, and the patient experienced no symptom relief.
asserted
patient → follow → relief
"We're left to kind of decide, 'Well, what now?'" Dombo said.
asserted
Dombo → leave → ?
We don't have a set guideline for how to be able to do this for women.
asserted
We → have → women
We have to rely on the art of medicine."
asserted
We → have → medicine
The latest federal meeting represents a critical step forward, according to Dombo, who believes grassroots advocacy from patients and clinicians is forcing regulatory action.
uncertain
advocacy → represent → action
"We're not going to stop knocking on the door, because there are several of us who believe that women deserve to be able to have access to just what they need," she said.
asserted
she → go → what
"Sexual health is part of your entire health," Dombo emphasized, expressing optimism that regulatory agencies will eventually adapt to support safer, standardized access.
asserted
agencies → emphasize → access
The Aporia
